SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-22-021564
Filing Date
2022-11-03
Accepted
2022-11-03 07:47:11
Documents
14
Period of Report
2022-11-03
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K kura-20221103.htm   iXBRL 8-K 64843
2 EX-99.1 kura-ex99_1.htm EX-99.1 196748
3 GRAPHIC img71811756_0.jpg GRAPHIC 10590
  Complete submission text file 0000950170-22-021564.txt   413988

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT kura-20221103_pre.xml EX-101.PRE 11070
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT kura-20221103_lab.xml EX-101.LAB 17944
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT kura-20221103.xsd EX-101.SCH 2486
8 EXTRACTED XBRL INSTANCE DOCUMENT kura-20221103_htm.xml XML 4709
Mailing Address 12730 HIGH BLUFF DRIVE, SUITE 400 SAN DIEGO CA 92130
Business Address 12730 HIGH BLUFF DRIVE, SUITE 400 SAN DIEGO CA 92130 (858) 500-8800
Kura Oncology, Inc. (Filer) CIK: 0001422143 (see all company filings)

IRS No.: 611547851 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37620 | Film No.: 221356287
SIC: 2834 Pharmaceutical Preparations